Published in J Natl Cancer Inst on September 21, 2005
Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet (2009) 7.07
Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn (2006) 4.68
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A (2007) 4.16
Epigenetics and colorectal cancer. Nat Rev Gastroenterol Hepatol (2011) 3.15
Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst (2009) 2.57
A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology (2009) 2.56
Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet (2010) 2.27
Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell (2014) 1.99
Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology (2008) 1.97
Clinical implications and utility of field cancerization. Cancer Cell Int (2007) 1.91
Epigenetic silencing of miR-137 is an early event in colorectal carcinogenesis. Cancer Res (2010) 1.88
Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia (2006) 1.84
Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a 'fusion' pathway to colorectal cancer. Histopathology (2006) 1.78
Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res (2008) 1.64
Aging and epigenetic drift: a vicious cycle. J Clin Invest (2014) 1.63
Colorectal cancer: a model for epigenetic tumorigenesis. Gut (2006) 1.62
Colorectal carcinoma: Pathologic aspects. J Gastrointest Oncol (2012) 1.59
Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut (2007) 1.53
Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue. Cancer Res (2010) 1.47
Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. PLoS One (2008) 1.46
DNA methylation, field effects, and colorectal cancer. J Natl Cancer Inst (2005) 1.44
Cancer stem cells: the lessons from pre-cancerous stem cells. J Cell Mol Med (2007) 1.38
DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer (2006) 1.36
Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer. Gastroenterology (2014) 1.32
Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer (2008) 1.31
Field defects in progression to gastrointestinal tract cancers. Cancer Lett (2007) 1.28
Profiling CpG island field methylation in both morphologically normal and neoplastic human colonic mucosa. Br J Cancer (2008) 1.27
Aberrant gene promoter methylation associated with sporadic multiple colorectal cancer. PLoS One (2010) 1.25
Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut (2006) 1.25
Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. Gastroenterology (2015) 1.24
DiseaseMeth: a human disease methylation database. Nucleic Acids Res (2011) 1.22
HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure. PLoS One (2013) 1.21
High quality assessment of DNA methylation in archival tissues from colorectal cancer patients using quantitative high-resolution melting analysis. J Mol Diagn (2009) 1.21
Endothelial cells enhance tumor cell invasion through a crosstalk mediated by CXC chemokine signaling. Neoplasia (2008) 1.21
Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiol Biomarkers Prev (2011) 1.19
DNA methylation and cancer diagnosis. Int J Mol Sci (2013) 1.18
MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers. Cancer Causes Control (2010) 1.16
Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol (2014) 1.16
CIMP and colon cancer gets more complicated. Gut (2007) 1.16
Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. Int J Cancer (2008) 1.15
Piwil2 expressed in various stages of cervical neoplasia is a potential complementary marker for p16. Am J Transl Res (2010) 1.13
Modulation of genetic and epigenetic biomarkers of colorectal cancer in humans by black raspberries: a phase I pilot study. Clin Cancer Res (2010) 1.12
Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer. Mol Cancer (2008) 1.11
Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. Gastroenterology (2009) 1.10
MethylPurify: tumor purity deconvolution and differential methylation detection from single tumor DNA methylomes. Genome Biol (2014) 1.09
Concordant DNA methylation in synchronous colorectal carcinomas. Cancer Prev Res (Phila) (2009) 1.08
The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer (2011) 1.08
Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer. BMC Cancer (2006) 1.08
Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br J Cancer (2013) 1.07
Nutritional factors and gender influence age-related DNA methylation in the human rectal mucosa. Aging Cell (2012) 1.04
Novel candidate colorectal cancer biomarkers identified by methylation microarray-based scanning. Endocr Relat Cancer (2011) 1.03
Genome-scale analysis of DNA methylation in colorectal cancer using Infinium HumanMethylation450 BeadChips. Epigenetics (2013) 1.02
Tumor-associated endothelial cells display GSTP1 and RARbeta2 promoter methylation in human prostate cancer. J Transl Med (2006) 1.02
Epigenomics in environmental health. Front Genet (2011) 1.02
Hydrophobic bile acids, genomic instability, Darwinian selection, and colon carcinogenesis. Clin Exp Gastroenterol (2008) 1.02
Using optical markers of nondysplastic rectal epithelial cells to identify patients with ulcerative colitis-associated neoplasia. Inflamm Bowel Dis (2011) 1.01
Simultaneous gallbladder and bile duct cancers: revisiting the pathological possibilities. HPB (Oxford) (2008) 1.00
Patterns of DNA methylation in the normal colon vary by anatomical location, gender, and age. Epigenetics (2014) 1.00
Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients. BMC Cancer (2010) 0.99
Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma. Clinics (Sao Paulo) (2011) 0.99
Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo. Cancer Res (2008) 0.96
Spatially resolved optical and ultrastructural properties of colorectal and pancreatic field carcinogenesis observed by inverse spectroscopic optical coherence tomography. J Biomed Opt (2014) 0.95
Quantitative evaluation of DNA hypermethylation in malignant and benign breast tissue and fluids. Int J Cancer (2010) 0.95
DNA methylation in circulating tumour DNA as a biomarker for cancer. Biomark Insights (2008) 0.95
Epigenetic changes in colorectal cancer. Chin J Cancer (2011) 0.94
Epigenetic differences in normal colon mucosa of cancer patients suggest altered dietary metabolic pathways. Cancer Prev Res (Phila) (2012) 0.94
Role of DNA methylation in head and neck cancer. Clin Epigenetics (2011) 0.94
Associations of Ki-ras proto-oncogene mutation and p53 gene overexpression in sporadic colorectal adenomas with demographic and clinicopathologic characteristics. Cancer Epidemiol Biomarkers Prev (2006) 0.94
Reversibility of aberrant global DNA and estrogen receptor-alpha gene methylation distinguishes colorectal precancer from cancer. Int J Clin Exp Pathol (2008) 0.93
Epigenetic alterations in RASSF1A in human aberrant crypt foci. Carcinogenesis (2006) 0.92
Demonstration of the usefulness of epigenetic cancer risk prediction by a multicentre prospective cohort study. Gut (2014) 0.92
Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer. Breast Cancer Res (2015) 0.91
Promoter methylation status of hMLH1, hMSH2, and MGMT genes in colorectal cancer associated with adenoma-carcinoma sequence. Langenbecks Arch Surg (2011) 0.91
Hormone therapy, DNA methylation and colon cancer. Carcinogenesis (2010) 0.91
Do we use the appropriate controls for the identification of informative methylation markers for early cancer detection? Genome Biol (2008) 0.91
DNA methylation profiles of primary colorectal carcinoma and matched liver metastasis. PLoS One (2011) 0.90
Investigation of nuclear nano-morphology marker as a biomarker for cancer risk assessment using a mouse model. J Biomed Opt (2012) 0.90
DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus. Clin Cancer Res (2012) 0.90
Predictive and prognostic factors in colorectal cancer: a personalized approach. Cancers (Basel) (2011) 0.89
Keratins in colorectal epithelial function and disease. Int J Exp Pathol (2012) 0.89
DNA methylation: a marker for carcinogen exposure and cancer risk. Environ Health Prev Med (2007) 0.89
Analysis of APC and IGFBP7 promoter gene methylation in Swedish and Vietnamese colorectal cancer patients. Oncol Lett (2012) 0.89
Occult progression by Apc-deficient intestinal crypts as a target for chemoprevention. Carcinogenesis (2013) 0.89
Distinct profiles of epigenetic evolution between colorectal cancers with and without metastasis. Am J Pathol (2011) 0.88
Examination of whole blood DNA methylation as a potential risk marker for gastric cancer. Cancer Prev Res (Phila) (2013) 0.88
Field cancerization in the colon: a role for aberrant DNA methylation? Gastroenterol Rep (Oxf) (2014) 0.88
Altered mucosal DNA methylation in parallel with highly active Helicobacter pylori-related gastritis. Gastric Cancer (2013) 0.87
Diagnostic utility of MS-MLPA in DNA methylation profiling of adenocarcinomas and neuroendocrine carcinomas of the colon-rectum. Virchows Arch (2012) 0.86
Role of MGMT as biomarker in colorectal cancer. World J Clin Cases (2014) 0.86
Epigenetics in the pathogenesis of rheumatoid arthritis. BMC Med (2014) 0.86
Epigenetic field defects in progression to cancer. World J Gastrointest Oncol (2013) 0.86
Colorectal advanced neoplasms occur through dual carcinogenesis pathways in individuals with coexisting serrated polyps. PLoS One (2014) 0.84
Expression and promoter methylation status of hMLH1, MGMT, APC, and CDH1 genes in patients with colon adenocarcinoma. Exp Biol Med (Maywood) (2015) 0.84
Toward a Molecular Classification of Colorectal Cancer: The Role of MGMT. Front Oncol (2013) 0.84
Methylation of MGMT and ADAMTS14 in normal colon MUCOSA: biomarkers of a field defect for cancerization preferentially targeting elder African-Americans. Oncotarget (2015) 0.83
Passenger mutations as a marker of clonal cell lineages in emerging neoplasia. Semin Cancer Biol (2010) 0.83
CpG island methylation in familial colorectal cancer patients not fulfilling the Amsterdam criteria. J Korean Med Sci (2008) 0.83
Myofibroblast-derived SFRP1 as potential inhibitor of colorectal carcinoma field effect. PLoS One (2014) 0.83
International network of cancer genome projects. Nature (2010) 20.35
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer (2006) 8.57
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood (2006) 8.38
A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res (2004) 7.92
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 6.87
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol (2009) 5.37
Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet (2007) 5.16
Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet (2008) 5.08
Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet (2011) 4.85
Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol (2012) 4.44
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2012) 4.42
SOX9 is required for the differentiation of paneth cells in the intestinal epithelium. Gastroenterology (2007) 4.17
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A (2007) 4.16
Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med (2002) 3.54
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood (2006) 3.48
Bayesian enrichment strategies for randomized discontinuation trials. Biometrics (2011) 3.39
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood (2005) 3.24
Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med (2005) 3.19
Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med (2002) 3.16
Widespread and tissue specific age-related DNA methylation changes in mice. Genome Res (2010) 2.99
LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One (2007) 2.99
Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res (2010) 2.82
Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res (2003) 2.80
A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol (2012) 2.77
Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med (2008) 2.74
Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol (2003) 2.72
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res (2002) 2.71
Epigenetics in cancer: what's the future? Oncology (Williston Park) (2011) 2.70
DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res (2006) 2.69
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant (2011) 2.63
CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res (2013) 2.57
Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One (2011) 2.57
A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology (2008) 2.56
Downregulation of histone H3 lysine 9 methyltransferase G9a induces centrosome disruption and chromosome instability in cancer cells. PLoS One (2008) 2.52
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res (2011) 2.52
Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer (2005) 2.49
Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov (2013) 2.49
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol (2009) 2.47
Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol (2002) 2.38
Epigenetic changes in colorectal cancer. Cancer Metastasis Rev (2004) 2.35
Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene (2005) 2.34
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood (2010) 2.25
DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol (2009) 2.23
Cancer epigenetics. CA Cancer J Clin (2010) 2.16
NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw (2010) 2.13
Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst (2005) 2.12
High-throughput methylation profiling by MCA coupled to CpG island microarray. Genome Res (2007) 2.09
Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals. Clin Cancer Res (2005) 2.07
Bayesian nonparametric nonproportional hazards survival modeling. Biometrics (2009) 2.05
DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst (2002) 2.04
Age-related DNA methylation changes in normal human prostate tissues. Clin Cancer Res (2007) 2.02
Template for Reporting Results of HER2 (ERBB2) Biomarker Testing of Specimens From Patients With Adenocarcinoma of the Stomach or Esophagogastric Junction. Arch Pathol Lab Med (2014) 2.02
Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clin Cancer Res (2007) 2.02
Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program (2004) 2.01
Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol (2006) 1.98
Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study. Gynecol Oncol (2004) 1.96
Selenium and colorectal adenoma: results of a pooled analysis. J Natl Cancer Inst (2004) 1.93
Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J Lab Clin Med (2003) 1.92
Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. Cancer Epidemiol Biomarkers Prev (2009) 1.88
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood (2013) 1.87
Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med (2008) 1.85
Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol (2005) 1.83
CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol (2002) 1.83
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood (2010) 1.82
Frequent CpG island methylation in serrated adenomas of the colorectum. Am J Pathol (2003) 1.82
Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res (2003) 1.79
Optimizing annealing temperature overcomes bias in bisulfite PCR methylation analysis. Biotechniques (2007) 1.78
Obtaining reliable information from minute amounts of RNA using cDNA microarrays. BMC Genomics (2002) 1.75
CIMP, at last. Gastroenterology (2005) 1.74
Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol (2006) 1.72
Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood (2008) 1.71
ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol (2009) 1.70
Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer (2008) 1.69
Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res (2007) 1.68
Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer (2011) 1.66
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood (2003) 1.65
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol (2006) 1.65
Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res (2008) 1.64
Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int (2013) 1.63
Decitabine--bedside to bench. Crit Rev Oncol Hematol (2006) 1.59
Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study. J Clin Oncol (2003) 1.59
Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases. Am J Surg Pathol (2003) 1.58
EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis. Cancer Res (2011) 1.58